|Articles|April 6, 2015
Safety and Efficacy Conerns in the Use of Intravitreal Anti-VEGF Therapy (Sponsored)
This supplement to Ophthalmology Times is sponsored by CME Matters, LLC, and supported by an unrestricted grant from Regeneron Pharmaceuticals, Inc.
Advertisement
Safety and Efficacy Conerns in the
Use of Intravitreal Anti-VEGF Therapy
The Historical Perspective on
Efficacy and Systemic Safety
This supplement to Ophthalmology Times is sponsored by CME Matters, LLC, and supported by an unrestricted grant from Regeneron Pharmaceuticals, Inc.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























